Alopecia

Dermatology·MeSH: Alopecia

Prevalence

200.0 / 100K

Incidence

20.0 / 100K/yr

25 drugs in development·16 companies·5 clinical trials

Drug Pipeline by Phase

Approved(4)

Drug	Company
finasteride	Teva Pharmaceutical Industries Limited (TEVA)
litfulo	PFIZER INC (PFE)
Olumiant	ELI LILLY & Co (LLY)
Olumiant®	ELI LILLY & Co (LLY)

Phase 3(5)

Drug	Company
amlitelimab	Sanofi (SNY)
Amlitelimab	Sanofi (SNY)
vdphl01	Veradermics Incorporated (MANE)
vdphl01 bid	Veradermics Incorporated (MANE)
vdphl01 qd	Veradermics Incorporated (MANE)

Phase 2(7)

Drug	Company
bempikibart	Q32 Bio Inc. (QTTB)
eq101	Equillium, Inc. (EQ)
fb-102	Forte Biosciences, Inc. (FBRX)
fb102	Forte Biosciences, Inc. (FBRX)
ly4005130	ELI LILLY & Co (LLY)
Rezpegaldesleukin	NEKTAR THERAPEUTICS (NKTR)
zumilokibart	Apogee Therapeutics, Inc. (APGE)

Phase 1(8)

Drug	Company
AQST-108	Aquestive Therapeutics, Inc. (AQST)
ARQ-252	Arcutis Biotherapeutics, Inc. (ARQT)
ARQ-255	Arcutis Biotherapeutics, Inc. (ARQT)
DA-020	Merus N.V. (MRUS)
DA-020 and Hyperforin	Merus N.V. (MRUS)
hcw9302	HCW Biologics Inc. (HCWB)
Platelet-Rich Plasma Injections	Accustem Sciences Inc. (ACUT)
Secretome	Accustem Sciences Inc. (ACUT)

Phase 2/Phase 3(1)

Drug	Company
DA-020	Applied Therapeutics, Inc. (APLT)

BioSniper tracks 25 drugs in development for Alopecia across 16 companies.

There are 5 clinical trials targeting Alopecia tracked by BioSniper.

The estimated prevalence of Alopecia is approximately 200.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.